Search Results - "Stein, Brian N."

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial by Vermorken, Jan B, Dr, Stöhlmacher-Williams, Jan, MD, Davidenko, Irina, MD, Licitra, Lisa, MD, Winquist, Eric, MD, Villanueva, Cristian, MD, Foa, Paolo, MD, Rottey, Sylvie, MD, Skladowski, Krzysztof, MD, Tahara, Makoto, MD, Pai, Vasant R, MD, Faivre, Sandrine, MD, Blajman, Cesar R, MD, Forastiere, Arlene A, MD, Stein, Brian N, MBBS, Oliner, Kelly S, PhD, Pan, Zhiying, PhD, Bach, Bruce A, MD

“…Summary Background Previous trials have shown that anti-EGFR monoclonal antibodies can improve clinical outcomes of patients with recurrent or metastatic…”
Get full text

A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6 by Hughes, Brett G.M., Guminski, Alexander, Bowyer, Samantha, Migden, Michael R., Schmults, Chrysalyne D., Khushalani, Nikhil I., Chang, Anne Lynn S., Grob, Jean-Jacques, Lewis, Karl D., Ansstas, George, Day, Fiona, Ladwa, Rahul, Stein, Brian N., Muñoz Couselo, Eva, Meier, Friedegund, Hauschild, Axel, Schadendorf, Dirk, Basset-Seguin, Nicole, Modi, Badri, Dalac-Rat, Sophie, Dunn, Lara A., Flatz, Lukas, Mortier, Laurent, Guégan, Sarah, Heinzerling, Lucie M., Mehnert, Janice M., Trabelsi, Sabiha, Soria-Rivas, Ainara, Stratigos, Alexander J., Ulrich, Claas, Wong, Deborah J., Beylot-Barry, Marie, Bossi, Paolo, Bugés Sánchez, Cristina, Chandra, Sunandana, Robert, Caroline, Russell, Jeffery S., Silk, Ann W., Booth, Jocelyn, Yoo, Suk-Young, Seebach, Frank, Lowy, Israel, Fury, Matthew G., Rischin, Danny

“…In the phase 2 EMPOWER-CSCC-1 study (NCT02760498), cemiplimab demonstrated antitumor activity against metastatic cutaneous squamous cell carcinoma (mCSCC) and…”
Get full text

Activation of Endothelial Extracellular Signal-Regulated Kinase Is Essential for Neutrophil Transmigration: Potential Involvement of a Soluble Neutrophil Factor in Endothelial Activation by Stein, Brian N, Gamble, Jennifer R, Pitson, Stuart M, Vadas, Mathew A, Khew-Goodall, Yeesim

“…During an inflammatory response induced by infection or injury, leukocytes traverse the endothelial barrier into the tissue space. Extravasation of leukocytes…”
Get full text

Dose modification for haematological toxicity: a survey of Australian medical oncologists by Cui, Wanyuan, Shingleton, Julia, Byrne, Liesel, Kelly, Aisling, King, Lisa, Smith, Phillipa, Lewis, Craig R., Stein, Brian N., Shapiro, Jeremy, Karapetis, Christos, Wong, Rachel

“…Background Evidence supporting dose modifications to reduce serious treatment‐related adverse events of antineoplastic therapy is limited and frequently based…”
Get full text

Stat6 Activation Is Essential for Interleukin-4 Induction of P-Selectin Transcription in Human Umbilical Vein Endothelial Cells by Khew-Goodall, Yeesim, Wadham, Carol, Stein, Brian N, Gamble, Jennifer R, Vadas, Mathew A

“…Chronic upregulation of P-selectin expression on the surface of the endothelium has been observed in and likely contributes to a number of chronic inflammatory…”
Get full text

An open-label, multicenter phase 1 study to characterize safety, tolerability, preliminary antitumor activity, and pharmacokinetics of VIP236 monotherapy in patients with advanced cancer by Vandross, Andrae L., Stein, Brian N., Coward, Jermaine, Sharma, Sunil, Johnson, Amy J., Birkett, Joseph, Huang, Xin, Frigault, Melanie M., Lerchen, Hans-georg, Stelte-Ludwig, Beatrix, Navarro, Tasheda, Peck, Jim, Gross, Wyatt, Izumi, Raquel, Hamdy, Ahmed M., Rodriguez Rivera, Ildefonso

“…TPS3168 Background: VIP236, a first-in-class SMDC, consists of an αvβ3 integrin small molecule binder, a peptide linker cleaved by neutrophil elastase (NE) in…”
Get full text

Phase Ib, international, dose-escalation study to evaluate the safety, pharmacokinetics (PK) and efficacy of ST-617 for the attenuation of oral mucositis (OM) in patients receiving chemoradiation (CRT) for head and neck (H&N) cancer by Osei-Fofie, Daniel, Wetter, Julie, Landers, Greg A., Kraus, Peter Alfred, Sukumaran, Shawgi, Mun, Hui, Stein, Brian N., Bray, Victoria Jane, Framroze, Bomi, Gelfand, Jeffrey, Song, Paul Y., Lategan, Andries, Dimitriu, Mikaela, Sonis, Stephen T.

“…Abstract only 6075 Background: OM is a common, painful, and costly toxicity associated with cytotoxic regimens used to treat H&N cancers, which may result in…”
Get full text

Prophylactic ciprofloxacin to prevent febrile neutropenia in adjuvant breast cancer patients receiving docetaxel (nonanthracycline) regimens by Okera, Meena, Stevenson, Ben W., Stein, Brian N., Singhal, Nimit, Parnis, Francis, Cheong, Kerry A., Bampton, Carolyn L., Bishnoi, Sarwan K., Kotasek, Dusan

“…Abstract only…”
Get full text

Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial by Stein, B N, Petrelli, N J, Douglass, H O, Driscoll, D L, Arcangeli, G, Meropol, N J

“…Cancer is most common in older age groups, but little information is available with regard to the impact of age on chemotherapy toxicity. This study was…”
Get more information